Unitree Soars 629% in Shanghai Debut: China's Humanoid Robot Champion Goes Public

China’s humanoid robotics industry just had its Nasdaq moment — on the Shanghai Stock Exchange. Unitree Robotics (宇树科技), the Hangzhou-based maker whose backflipping robot dogs and budget humanoids have made it the world’s largest humanoid robot company by sales, staged one of the most explosive market debuts in the history of China’s A-share market on Wednesday, August 19, 2026. Shares opened at 1,100 yuan — a 629% pop above the 150.80 yuan IPO price — before settling at 845 yuan, a first-day gain of roughly 460% that left the company with a market value around $48–50 billion.

The numbers behind the pop

The offering itself was modest by mega-cap standards. Unitree issued 40.446 million new A-shares at 150.80 yuan ($22.34) each, raising approximately $904 million and valuing the company at about 61 billion yuan, or $9.04 billion, before the first trade. There was no secondary sale by existing shareholders — a signal that early backers, a roster that includes Alibaba, Tencent, China Mobile Capital, Ant Group, and Geely Capital, preferred to hold.

What followed was extraordinary even by the standards of China’s frenetic STAR Market and main-board debuts. At the intraday peak, Unitree’s market capitalization approached $66 billion, briefly outpacing the debut surge of CXMT, China’s homegrown DRAM champion. Demand was unprecedented: the retail tranche was reportedly oversubscribed thousands of times over, with some accounts putting the figure near 8,000x — meaning the odds of a successful retail allocation were around 0.018%. Analysts noted the float was unusually small relative to demand, structurally amplifying the surge.

Founder and CEO Wang Xingxing (王興興), a former DJI engineer who started Unitree in August 2016 building quadruped robots for hobbyists, saw his personal stake catapult his net worth to roughly $16 billion, according to Forbes estimates.

Real revenue, real profit — at robot-industry scale

What separates Unitree’s debut from a typical speculative frenzy is the underlying business. According to the IPO prospectus:

• 2025 revenue reached 1.708 billion yuan (~$252 million), up 335% year-on-year.
• The company shipped 5,511 humanoid units (across the G1, H1, H2, and R1 lines) in 2025 — the largest humanoid shipment figure disclosed by any manufacturer.
• It has sold more than 33,000 quadruped robot dogs, with entry pricing around $1,600, a price point that made legged robotics accessible to researchers, educators, and hobbyists worldwide.
• Critically, Unitree reported a net profit on an adjusted basis — a rarity in a sector where most players burn cash on prototypes and pilot programs. First-quarter 2026 revenue reportedly surged 68% year-on-year to about $62 million, with adjusted profitability intact.

That combination — volume leadership, revenue hypergrowth, and actual profits — is why Unitree is widely described as China’s first “pure play” public humanoid company, and why the debut is being read as a referendum on the entire embodied-AI sector.

The valuation debate

Even bulls acknowledge the price. At the IPO price of 150.80 yuan, Unitree was already trading at roughly 219 times projected 2025 earnings and 36 times sales. At the 845-yuan close, those multiples expanded by more than five-fold, implying a price-to-sales ratio approaching 200 on trailing revenue — territory normally reserved for early-stage venture bets, not a company with a ~$250 million revenue base.

Skeptics point to structural risks flagged in Unitree’s own filing: U.S. sales accounted for 18.39% of revenue, exposing the company to tariff and export-control risk at a moment when Washington is weighing restrictions on Chinese robotics supply chains. Competition is also intensifying, both from domestic rivals — AgiBot, UBTech, Galaxy General, and dozens of startups subsidized by local governments — and from Tesla’s Optimus program, Figure AI, and Boston Dynamics in the West.

Defenders counter that the market is pricing Unitree less as a hardware vendor and more as China’s category-defining platform for embodied intelligence: the company controls its actuators, motors, and control software stack, and its low-cost manufacturing engine has consistently undercut Western competitors by an order of magnitude on price.

Why it matters beyond the stock ticker

First, the debut hands China’s humanoid robotics ecosystem a public pricing benchmark. Every private fundraising round for AgiBot, UBTech, and the rest will now be negotiated in Unitree’s shadow — and as China Daily noted, competitors suddenly face “a much tougher valuation test” from investors who can compare pitch decks against audited numbers.

Second, it validates the low-cost, high-volume strategy. While Western humanoid developers chase six-figure general-purpose laborers for warehouse pilots, Unitree spent a decade proving that aggressive cost engineering — $1,600 robot dogs, $16,000-class G1 humanoids — could build a real business with real margins. That playbook now has a public-market stamp of approval worth tens of billions of dollars.

Third, the listing deepens the policy stakes. A $50 billion public champion tied to Chinese retail investors makes the embodied-AI race even more explicitly national on both sides of the Pacific. The same week as the debut, Reuters’ AI Weekly paired the Unitree story with fresh disclosures about Anthropic’s forward revenue — a reminder that capital markets are now the primary scoreboard for the AI race, and China has just posted a score.

Whether the 845-yuan close proves durable is an open question; even optimistic analysts concede the float dynamics that fueled the pop could work in reverse. But as a milestone — China’s first publicly traded humanoid robot maker, the world’s highest-volume humanoid builder, profitable, and instantly among the most valuable robotics companies on Earth — Unitree’s Shanghai debut is the moment the embodied-AI trade went mainstream.